论文部分内容阅读
目的:观察抗癌防移片联合化疗治疗大肠癌肝转移的临床疗效.方法:将60例大肠癌肝转移患者,随机分为抗癌防移片联合化疗组(即治疗组)30例,单纯化疗组(即对照组)30例,比较两者近期客观疗效、生活质量、癌胚抗原(CEA)、不良反应等指标,并进行统计分析.结果:治疗组总缓解率明显优于对照组,KPS评分改善明显优于对照组,血清CEA水平下降明显优于对照组,毒副作用发生率明显低于对照组,差异均有统计学意义(P＜0.05).结论:抗癌防移片联合化疗治疗大肠癌肝转移可以减轻患者症状,提高疗效,改善生活质量,降低血清CEA水平,减少不良反应.“,”Objective: To observe the clinical efficacy of Kang'ai Fangyi tablets combined with chemotherapy on the treatment of of colorectal carcinoma patients with liver metastasis. Methods: A total of 60 patients with liver metastatic colorectal cancer were randomly divided into treatment group (30 cases) and control group (30 cases). We then compared the short-term effects, quality of life, carcinoembryonic antigen (CEA), adverse reactions and other indicators by statistical analyses. Results: The remission rate in treatment group was better than control group for hepatic metastasis of colorectal cancer. The KPS score was significantly better than the control group. The level of serum CEA decreased significantly than the control group. The incidence of adverse effects was significantly lower than the control group. Conclusion: The combination of Kang'ai Fangyi tablets and chemotherapy can relieve the symptoms, improve the curative effect, improve the quality of life, reduce the serum CEA level and reduce the adverse reactions in colorectal cancer patients with liver metastasis.